- Sarcoma
-
Enrichment of Wee1/CDC2 and NF-κB Signaling Pathway Constituents Mutually Contributes to CDDP Resistance in Human Osteosarcoma
-
Zhengbo Hu, Lugen Li, Wenxing Lan, Xiao Wei, Xiangyuan Wen, Penghuan Wu, Xianliao Zhang, Xinhua Xi, Yufa Li, Liqi Wu, Wenhu Li, Xiaohong Liao
-
Cancer Res Treat. 2022;54(1):277-293. Published online May 11, 2021
-
DOI: https://doi.org/10.4143/crt.2021.320
-
-
 Abstract
 PDF PubReader ePub
- Purpose
Osteosarcoma (OS) universally exhibits heterogeneity and cisplatin (CDDP) resistance. Although the Wee1/CDC2 and nuclear factor кB (NF-κB) pathways were reported to show abnormal activation in some tumor cells with CDDP resistance, whether there is any concrete connection is currently unclear. We explored it in human OS cells.
Materials and Methods
Multiple OS cell lines were exposed to a Wee1 inhibitor (AZD1775) and CDDP to assess the half-maximal inhibitory concentration values. Western blot, coimmunoprecipitation, confocal immunofluorescence, cell cycle, and Cell Counting Kit-8assays were performed to explore the connection between the Wee1/CDC2 and NF-κB pathways and their subsequent physiological contribution to CDDP resistance. Finally, CDDP-resistant PDX-OS xenograft models were established to confirm that AZD1775 restores the antitumor effects of CDDP.
Results
A sensitivity hierarchy of OS cells to CDDP and AZD1775 exists. In the highly CDDP-tolerant cell lines, Wee1 and RelA were physically crosslinked, which resulted in increased abundance of phosphorylated CDC2 (Y15) and RelA (S536) and consequent modulation of cell cycle progression, survival, and proliferation. Wee1 inhibition restored the effects of CDDP on these processes in CDDP-resistant OS cells. In addition, animal experiments with CDDP-resistant PDX-OS cells showed that AZD1775 combined with CDDP not only restored CDDP efficacy but also amplified AZD1775 in inhibiting tumor growth and prolonged the median survival of the mice.
Conclusion
Simultaneous enrichment of molecules in the Wee1/CDC2 and NF-κB pathways and their consequent coactivation is a new molecular mechanism of CDDP resistance in OS cells. OS with this molecular signature may respond well to Wee1 inhibition as an alternative treatment strategy.
-
Citations
Citations to this article as recorded by  - Wee1 inhibitor PD0166285 sensitized TP53 mutant lung squamous cell carcinoma to cisplatin via STAT1
Qi Li, Wenjie Yang, Qingyi Zhang, Daoming Zhang, Jun Deng, Binxin Chen, Ping Li, Huanqi Zhang, Yiming Jiang, Yangling Li, Bo Zhang, Nengming Lin
Cancer Cell International.2024;[Epub] CrossRef - BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1
Aditya Mandapati, Zhibin Ning, Akanksha Baharani, Kiven Erique Lukong
Cellular Signalling.2023; 108: 110723. CrossRef - Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process
Yu-Li Su, Ling-Yi Xiao, Shih-Yu Huang, Chia-Che Wu, Li-Chung Chang, Yi-Hua Chen, Hao-Lun Luo, Chun-Chieh Huang, Ting-Ting Liu, Jei-Ming Peng
Cells.2023; 12(11): 1471. CrossRef - Network pharmacology-based research on the effect of angelicin on osteosarcoma and the underlying mechanism
Yafang Zhang, Junqiang Wei, Lingwei Kong, Mingze Song, Yange Zhang, Xiangyu Xiao, Haiying Cao, Zhehong Li, Ning Yang, Yu Jin
Aging.2023;[Epub] CrossRef - Identification of Cell Subpopulations and Interactive Signaling Pathways From a Single-Cell RNA Sequencing Dataset in Osteosarcoma: A Comprehensive Bioinformatics Analysis
Rong Wu, Xiaojie Dou, Haidong Li, Zhenguo Sun, Heng Li, Yuxin Shen, Wei Weng, Jikang Min
Frontiers in Oncology.2022;[Epub] CrossRef - MicroRNAs and osteosarcoma: Potential targets for inhibiting metastasis and increasing chemosensitivity
Negin Soghli, Gordon A. Ferns, Fatemeh Sadeghsoltani, Durdi Qujeq, Tooba Yousefi, Mostafa Vaghari-Tabari
Biochemical Pharmacology.2022; 201: 115094. CrossRef - Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFα Resistance in Head and Neck Cancers
Zhengbo Hu, Ramya Viswanathan, Hui Cheng, Jianghong Chen, Xinping Yang, Angel Huynh, Paul Clavijo, Yi An, Yvette Robbins, Christopher Silvin, Clint Allen, Pinar Ormanoglu, Scott Martin, Shaleeka Cornelius, Anthony Saleh, Zhong Chen, Carter Van Waes, Ethan
Molecular Cancer Research.2022; 20(6): 867. CrossRef - Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma
Yang Zhou, Gai Li, Hu Li, Fuchong Lai, Pingguo Duan, Ming Cheng, Fu Wang
Journal of Immunology Research.2022; 2022: 1. CrossRef - Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment
Cassidy M. Van Stiphout, Anita K. Luu, Alicia M. Viloria-Petit
Cancers.2022; 14(19): 4544. CrossRef
-
6,014
View
-
176
Download
-
9
Web of Science
-
9
Crossref
|
KCA
